Trial Profile
A phase I study of FB002 for the treatment of solid tumours
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 17 Jan 2018
Price :
$35
*
At a glance
- Drugs FB 002 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 22 Dec 2017 According to a Eloxx Pharmaceuticals media release, Eloxx Pharmaceuticals acquired Sevion Therapeutics, and the company is called as Eloxx Pharmaceuticals.
- 29 Jul 2014 New trial record